出血性疾病治疗市场规模、份额、成长分析，按疾病类型、治疗类型、药物类别划分 - 产业预测，2024-2031 年

Bleeding Disorders Treatment Market Size, Share, Growth Analysis, By Disorder Type, By Treatment Type, By Drug Class(Plasma Derived Coagulation Factor ) - Industry Forecast 2024-2031

出版日期: 2024年06月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年，全球出血性疾病治疗市场规模为142.9亿美元，预测期内（2024-2031年）复合年增长率为8.3%，从2023年的154.8亿美元到2031年，预计将增长至29.29美元十亿。

全球出血性疾病治疗市场受到几个关键因素的推动，例如血友病和血管性血友病等疾病的盛行率不断增加，这些疾病需要先进的治疗性介入。止血控制的技术进步，例如重组凝血因子和基因治疗方案的开发，进一步促进了市场成长。然而，挑战包括先进治疗方法的成本高昂以及某些地区的取得机会有限。从地区来看，北美和欧洲因其发达的医疗基础设施而占据市场主导地位。重要趋势包括预防性治疗的采用和基因疗法的持续研究，这正在重塑全球出血性疾病的治疗模式。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Takeda Pharmaceutical Company Limited
Bayer AG
Biogen Inc.
CSL Behring（CSL Limited）
Novo Nordisk A/S
Pfizer Inc.
Grifols SA
Sanofi SA
Johnson & Johnson
Octapharma AG
Alnylam Pharmaceuticals Inc.
Roche Holding AG
Shire Plc.（earlier Baxalta）（Ireland）
AbbVie Inc.
Wellona Pharma
Sobi International AB
BioMarin Pharmaceutical, Inc.
UniQure NV
Pharming Group NV
HEMA BioSciences

简介目录

Product Code: SQMIG35J2106

Global Bleeding Disorders Treatment Market size was valued at USD 14.29 billion in 2022 and is poised to grow from USD 15.48 billion in 2023 to USD 29.29 billion by 2031, at a CAGR of 8.3% during the forecast period (2024-2031).

The global market for treating bleeding disorders is propelled by several key factors, including the increasing incidence of conditions like hemophilia and von Willebrand disease, necessitating advanced therapeutic interventions. Technological advancements in hemostasis control, such as the development of recombinant clotting factors and gene therapy options, further contribute to market growth. Challenges, however, stem from the high cost of advanced treatments and limited access in certain regions. Geographically, North America and Europe dominate the market due to well-established healthcare infrastructure. Significant trends include the adoption of prophylactic treatments and ongoing research in gene therapy, reshaping the landscape of bleeding disorder treatment worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bleeding Disorders Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bleeding Disorders Treatment Market Segmental Analysis

The global Bleeding Disorders Treatment market is segmented into disorder type, treatment type, drug class and region. Based on disorder type, it is divided into Hemophilia A, Hemophilia B, Von Willebrand Disease, Others. Based on treatment type, the market is segmented into Recombinant clotting factors, plasma-derived clotting factors, desmopressin, antifibrinolytics, gene therapy. Based on drug class, the market is segmented into Plasma Derived Coagulation Factor (Factor VIII, Factor IX, Factor for Von Willebrand Disease, Activated Prothrombin Complex Concentrate), Recumbent Coagulation Factor (Factor VIII, Factor for Von Willebrand Disease, Factor IX), Desmopressin, Antifibrinolytics, Fibrin Sealants, Others. Based on region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.

Drivers of the Global Bleeding Disorders Treatment Market

The increasing prevalence of bleeding disorders, such as hemophilia and von Willebrand disease, fuels a rising need for advanced treatment options. Technological advancements in hemostasis management, encompassing recombinant clotting factors and gene therapy strategies, contribute to more effective and precise interventions, addressing this growing demand with enhanced efficacy.

Restraints in the Global Bleeding Disorders Treatment Market

One of the main obstacles in the marketplace is the significant cost associated with advanced treatment methods, which acts as a major barrier, limiting access to these treatments in certain regions and for financially disadvantaged patients. Moreover, regulatory intricacies and the lengthy approval processes for new treatments also impede the swift introduction of innovative solutions.

Market Trends of the Global Bleeding Disorders Treatment Market

There's a burgeoning awareness surrounding personalized medicine, which customizes treatments according to individual patient characteristics to enhance effectiveness and minimize adverse effects. Gene therapy advancements are gaining traction as a revolutionary development, demonstrated by ongoing research and clinical trials showing promise in providing a curative approach for certain bleeding disorders. Furthermore, there's a growing emphasis on prophylactic treatments, prioritizing the prevention of bleeding episodes over reactive interventions.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Pricing Analysis
Start Up Analysis
Regulatory Landscape
Patent Analysis
Pipeline Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Bleeding Disorders Treatment Market by Disorder Type

Market Overview
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

Bleeding Disorders Treatment Market by Treatment Type

Market Overview
Recombinant Clotting Factors
Plasma-derived Clotting Factors
Desmopressin
Antifibrinolytics
Gene Therapy

Bleeding Disorders Treatment Market by Drug Class

Market Overview
Plasma Derived Coagulation Factor
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
Recumbent Coagulation Factor
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
Desmopressin
Antifibrinolytics
Fibrin Sealants

Bleeding Disorders Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (CSL Limited)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire Plc. (earlier Baxalta) (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wellona Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sobi International AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UniQure NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharming Group N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HEMA BioSciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments